Tag Archives: lipid-modifying therapy
January 2009 Br J Cardiol 2009;16:16-14
New lipid-modifying therapy phase 3 study shows reduced flushing
BJCardio editorial staff
Treatment with 2 g of the nicotinic acid/laropiprant combination produced a significant 18% reduction from baseline in low-density lipoprotein cholesterol (LDL-C) and a 26% reduction in triglycerides compared to placebo across weeks 12-24. In addition, patients treated with the combination experienced significantly less flushing compared with those treated with extended-release nicotinic acid (0.2 days/week versus 0.7 days/week respectively). Some 69% of patients treated with 1 g of the combination reported either no flushing symptoms, or mild flushing symptoms during the first week of treatment, compared to 44% of those who received extended
March 2005 Br J Cardiol 2005;12:118-22
Dyslipidaemia in ethnic populations: special considerations
Anthony H Barnett
No content available
For healthcare professionals only
